Product Images Aripiprazole

The text mentions Figure 1, illustrating the Effect of Other Drugs on Aripiprazole Pharmacokinetics. The figure likely shows data related to the impact of other drugs on the pharmacokinetics of aripiprazole. It suggests there are changes in pharmacokinetics when aripiprazole is influenced by different drugs, which could be crucial information for healthcare professionals and researchers.*

This is a description of "The Effect of Other Drugs on Dehydro-Aripiprazole Pharmacokinetics". It shows the impact of various drugs on Aripiprazole. The figure displays changes in Dehydro-Aripiprazole levels with different drugs, including anti-B-blockers and over-the-counter medications. The chart demonstrates the relative change concerning the reference levels without interacting drugs over a specified time period.*

This is a list showing the effect of Aripiprazole on the pharmacokinetics of other drugs. It includes the fold change and 90% confidence interval for various drugs such as dextromethorphan, warfarin, omeprazole, venlafaxine, escitalopram, and others. The chart also displays changes relative to a reference value.*

This text provides information about the effect of intrinsic factors on the pharmacokinetics of Aripiprazole in special populations. It discusses the impact of factors such as CYP2D6 metabolizer status, gender, age, hepatic impairment, and renal impairment on the drug's absorption (AUC) and peak concentration (Cmax). The text suggests that these factors can influence how the body processes Aripiprazole and may require adjustments in dosing or monitoring in specific patient populations.*

This is not readable.*

This figure shows the Kaplan-Meier estimation of the cumulative proportion of patients with relapse in Schizophrenia Study 5 comparing Aripriprazole and Placebo over time. The x-axis represents the days from randomization, while the y-axis shows the proportion of patients with relapse. The number of subjects at risk are also displayed in the table below the graph, illustrating the progressive decrease in subjects as the study progresses. An important tool in analyzing treatment efficacy and patient outcomes in clinical trials.*

This is a Kaplan-Meier estimation graph displaying the cumulative proportion of patients with relapse in Bipolar Study 7 comparing Avipriprazole to placebo over time. The graph shows the proportion of patients with relapse at different time points and the number of subjects at risk in each group.*

This is a Kaplan-Meier estimation graph displaying the cumulative proportion of patients experiencing relapse to any mood event in a bipolar study. The graph compares the outcomes between Aripiprazole and Placebo. The data shows the number of subjects at risk over time, along with the proportion of relapse for each group. The x-axis represents days from randomization, while the y-axis represents the proportion with relapse.*

This is a description of Aripiprazole 10mg tablets relabeled by Proficient Rx LP. The tablets are white to off-white, round, uncoated, and each tablet contains 10 mg of aripiprazole, USP. The tablets are imprinted with "10" on one side and "18" on the other side. The product ID is XA023690, and it is manufactured by TORRENT PHARMACEUTICALS LTD. It is recommended to store the medication at 20°-25°C (68°-77°F) and to keep it out of the reach of children. The lot number for this batch is 00000. Each pack contains 90 tablets, and the National Drug Code (NDC) for this product is 82804-236-90.*